Pharmaceutical and biotech companies are spending years, and millions of dollars, developing drugs or promising new biologics with the hope of saving or enhancing patients’ lives. It's a race to the finish in some cases, and the quicker a company can get its product to patients the better.
This e-book will help you determine if a rapid launch is an option for you.
Mary Szela spent 25 years in Big Pharma and the last seven at three small biotechs. The CEO Of TriSalus Life Sciences discusses how she adapted during these career changes and some of the difficulties she encountered along the way.
Dicerna shows how the multitude of “co-opportunities” of COVID in the RNA space has further encouraged companies to exploit the unique attributes of those approaches well beyond dealing with the immediate viral threat.
Allan Shaw rejoins theBusiness of Biotechpodcast with candid commentary on how the FDA is doing to keep up with the unprecedented pace of biopharma innovation. Listen now and subscribe so you never miss an episode.
Josh Brumm, CEO of Dyne Therapeutics, discusses some of the pros to pitching virtually. Keith Vendola, M.D, CSO and head of strategy at Rezolute, adds to the conversation by discussing the difficulty of making a human connection via Zoom.
Amid this opportunity for generic drug makers to capitalize on patent expiration, they’re facing struggles around pricing power. COVID-19 also exposed the fragility of supply chains that were built with economic efficiency rather than resiliency in mind.
Will decentralized clinical trials continue to be a hot topic even after the pandemic or will pharma companies revert to their old ways. Our guest, ClinicalLeader.com editor, Ed Miseta, weighs in on this timely topic.